[Comment on the contribution by H. Willenberg on problems in classification of covert self-injury and development of an alternative suggestion].

Psychother Psychosom Med Psychol

Rothaarklinik, Klinik für Psychosomatische Medizin, Bad Berleburg.

Published: June 1995

Download full-text PDF

Source

Publication Analysis

Top Keywords

[comment contribution
4
contribution willenberg
4
willenberg problems
4
problems classification
4
classification covert
4
covert self-injury
4
self-injury development
4
development alternative
4
alternative suggestion]
4
[comment
1

Similar Publications

Prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma through ultrasound elastography.

World J Gastroenterol

January 2025

Department of Radiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.

In this article, we comment on the article by Cheng published in recently. Posthepatectomy liver failure (PHLF) remains a leading cause of hepatectomy-related mortality and can be evaluated according to liver reserve function. Liver stiffness (LS) measured by ultrasonic elastography and spleen area demonstrate a strong correlation with hepatic proliferation, fibrosis, and portal vein congestion, thus indirectly reflecting liver reserve function.

View Article and Find Full Text PDF

Inavolisib: First Approval.

Drugs

January 2025

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Inavolisib (Itovebi) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being developed by Genentech, a member of the Roche group, for the treatment of solid tumours. On 10 October 2024, inavolisib received its first approval in the USA in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. In the EU and other countries worldwide, regulatory review of inavolisib is currently underway.

View Article and Find Full Text PDF

Flurpiridaz F 18: First Approval.

Am J Cardiovasc Drugs

January 2025

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.

View Article and Find Full Text PDF

In sports training, personalized skill assessment and feedback are crucial for athletes to master complex movements and improve performance. However, existing research on skill transfer predominantly focuses on skill evaluation through video analysis, addressing only a single facet of the multifaceted process required for skill acquisition. Furthermore, in the limited studies that generate expert comments, the learner's skill level is predetermined, and the spatial-temporal information of human movement is often overlooked.

View Article and Find Full Text PDF

New national climate plans offer the best opportunity yet to secure a healthy and stable future.

Lancet Planet Health

January 2025

Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC 3052, Australia. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!